SCHEMBL2064095

SCHEMBL2064095

C[SiH](C)OC(c1c(F)cccc1-c1ccc2nc(-c3ccc(Cl)cc3)cn2c1)C(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 8/20 0.50
KCNH2 Q12809 2/20 0.46
ALDH1A3 P47895 5/20 0.45
ALDH1A1 P00352 3/20 0.45
RAB9A P51151 4/20 0.44
NPC1 O15118 3/20 0.44
CYP2C9 P11712 1/20 0.41
APP P05067 1/20 0.39
ABL1 P00519 1/20 0.38
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2063969 0.92 ALDH1A3 (0.46) NR4A2KCNH2ALDH1A3ALDH1A1RAB9A
SCHEMBL2064626 0.88 ABL1 (0.40) NR4A2ABL1
SCHEMBL3430238 0.84 F2RL3 (0.39) NR4A2ALDH1A3ALDH1A1RAB9ANPC1
SCHEMBL2063438 0.80 NR4A2 (0.42) NR4A2KCNH2ALDH1A3ALDH1A1RAB9A
SCHEMBL2064144 0.79 NR4A2 (0.40) NR4A2KCNH2ABL1
SCHEMBL219946 0.73 HPGDS (0.37) NR4A2ALDH1A3ALDH1A1RAB9ANPC1
SCHEMBL2064094 0.72 NR4A2 (0.54) NR4A2KCNH2ALDH1A3ALDH1A1RAB9A
SCHEMBL2063551 0.71 NR4A2 (0.77) NR4A2KCNH2ALDH1A3ALDH1A1RAB9A
SCHEMBL2063837 0.70 NR4A2 (0.65) NR4A2KCNH2ALDH1A3ALDH1A1RAB9A
SCHEMBL2063520 0.70 NR4A2 (0.66) NR4A2KCNH2ALDH1A3ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2262803-B1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[L,2-A] PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2012-10-17 EP disclosed
US-8148370-B2 Polysubstituted derivatives of 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, and preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2012-04-03 US disclosed
US-20110065699-A1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065699-A1 POLYSUBSTITUTED DERIVATIVES OF 2-ARYL-6-PHENYL-IMIDAZO[1,2-a]PYRIDINES, AND PREPARATION AND THERAPEUTIC USE THEREOF ABL1, JAK2, REN NR4A2 1531/4885KCNH2 1429/4885ALDH1A3 1255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.